Clinical TrialMay 4, 2026, 04:08 PM
ORIC Pharma Selects Rinzimetostat Phase 3 Dose; Trial Starts 1H 2026
AI Summary
ORIC Pharmaceuticals reported Q1 2026 financial results and provided operational updates, highlighting the selection of rinzimetostat's Recommended Phase 3 Dose (RP3D) for the Himalayas-1 global registrational trial in post-abiraterone mCRPC, expected to begin in 1H 2026. Clinical data for rinzimetostat demonstrated a differentiated safety profile and landmark rPFS rates superior to standard-of-care therapies. The company also reported $419.7 million in cash and investments, providing a runway into 2H 2028, and anticipates several enozertinib clinical updates in 2H 2026.
Key Highlights
- Rinzimetostat 400 mg once daily selected as Recommended Phase 3 Dose for Himalayas-1 trial.
- Himalayas-1 global Phase 3 registrational trial in mCRPC expected to initiate in 1H 2026.
- Rinzimetostat showed landmark rPFS rates of 93%, 84%, and 84% at 3, 4, and 5 months.
- Cash, cash equivalents, and investments totaled $419.7 million as of March 31, 2026.
- Cash runway expected into 2H 2028, beyond primary endpoint readout of first Phase 3 trial.
- R&D expenses increased to $31.4 million in Q1 2026 from $24.6 million in Q1 2025.
- Net loss was $(35.767) million in Q1 2026, or $(0.34) per share.